FDA Approved Subcutaneous Isatuximab: Advancing Anti-CD38 Therapy Delivery in Multiple Myeloma

Sarclisa (isatuximab-irfc) Approved as a Subcutaneous Injection for ...

Sarclisa (isatuximab-irfc) Approved as a Subcutaneous Injection for Multiple Myeloma by the FDA Today, July 9, 2026, the U.S. FDA "approved

FDA Approves Subcutaneous Isatuximab for Multiple Myeloma

The FDA approved the subcutaneous (SC) administration of the anti-CD38 antibody isatuximab-irfc (Sarclisa) in multiple myeloma, based on non

FDA Approves Subcutaneous Sarclisa Escena for Multiple Myeloma

FDA approved Sarclisa Escena (isatuximab-irfc), a subcutaneous formulation of Sanofi's Sarclisa, for the treatment of multiple myeloma acros

Press Release: Sanofi's subcutaneous Sarclisa Escena approved in the US ...

The US Food and Drug Administration (FDA) has approved subcutaneous (SC) Sarclisa (isatuximab-irfc) Escena in combination with standard-of-c

<![CDATA[FDA Approves Subcutaneous Isatuximab in Multiple Myeloma]]>

<![CDATA[Isatuximab Wins FDA Approval, Becoming Second Subcutaneous Anti-CD38 for Multiple Myeloma]]>